A major pharmaceutical company based in New Jersey is apparently setting aside funds to settle commercial litigation over schizophrenia drug Risperdal and other medications. Johnson & Johnson has already made several recalls of the drug and is planning to designate an additional $600 million to cover potential settlements of civil lawsuits related to its marketing of Risperdal and other drugs.
An insurance brokerage firm consented to paying $4.75 million this week to the state of Ohio in order to settle an antitrust commercial litigation case. Marsh & McLennan Companies (MMC) faced bid-rigging and kickback scheme allegations from the State Attorney General's Office. MMC had been accused of working covertly with insurance firms to remove competition from the commercial casualty insurance marketplace.